一心二门 OP : Both startups and expansion come with significant risks—good luck…

一心二门 : This is a dermatological drug whose efficacy has already been validated in the U.S., Japan, and South Korea, and which benefits from a sufficiently long patent protection period. Given its current strong cash position and assured supply chain, it is expected that while deepening its presence in the U.S. market, the company will fully leverage its existing sales network to expand distribution of the drug and further enter markets such as Canada, Mexico, and Europe through licensing and other arrangements. A rebound in the stock price in the second half of the year—back to, or even slightly above, its most recent deeply discounted financing price—is not out of reach, though the real breakoutis likely to come next year or the year after. What interests me most is this: once the business reaches a certain scale, will they sell it, when will they sell, and to whom?

一心二门 : This isn't a short-term speculative stock like DRO, but it has significant potential if you can hold it for six months to a year.